When starting a new treatment, it’s only natural that you may have questions. Your doctor will show you how to inject PRALUENT. See the detailed Instructions for Use below for information about the right way to prepare and give the PRALUENT injections at home with the easy to use pre-filled pen. Or, click one of these links to download and print:
Note: if you have been prescribed 300 mg once monthly,
please utilize the Instructions For Use – Pen 150 mg.
A MyPRALUENT® nurse is on call 7 days a week, Monday to Friday 8:00 AM to 11:00 PM EST
and Saturday to Sunday 8:00 AM to 8:00 PM EST, to provide self-injection support and
training. Just call us at 1-844-PRALUENT (1-844-772-5836) and press 1.
The ready-to-use PRALUENT Pen was
designed for self-injection at home
The yellow safety needle cover keeps
the needle hidden throughout the
A "click" sound tells you that the injection
The window turns yellow when the
injection is completed so you know
the full dose has been delivered
Before you start your injection, you will need:
1 cotton ball
or gauze pad
A sharps disposal
For self-injecting the monthly 300 mg dose,
prepare two 150 mg pens.
If needed, patients may keep PRALUENT at room temperature up to 77°F (25°C) for a maximum of 30 days in original carton to protect from light
The instructions below use the 75 mg pen as an example
DO NOT touch the yellow safety needle cover
Your thumb should not touch the green button yet
The pen will not work if the yellow safety needle cover is not pushed all the way down
When self-injecting the monthly 300 mg dose, repeat ALL steps with a second 150 mg pen at a different injection site
*Eligible patients with commercial insurance not funded through a government healthcare program subject to an annual cap and other program terms and restrictions. This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs.
†Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in the PRALUENT randomized clinical trial program (ODYSSEY). The I-TAQ data is a 22-item, self-administered questionnaire, developed as a measure of injection-treatment acceptance for use in patients who inject their medications via subcutaneous injections.